The strong buying interest from three major passive managers, especially UBS's outsized move, suggests growing confidence in Genmab’s fundamentals or pipeline progress. Traders should monitor for follow-on buying and potential inclusion in broader ETFs or benchmark indices.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $29.65entry
- T+1 · 9mo ago −6.71%α −5.80% · $27.66
- T+5 · 8mo ago −8.13%α −6.92% · $27.24
- T+20 · 8mo ago −12.88%α −4.95% · $25.83
- T+60 · 6mo ago −9.31%α −18.64% · $26.89
How similar events traded
Executive Summary
Three major passive institutions, Morgan Stanley, Schwab, and UBS, significantly increased their positions in Genmab A/S during Q4 2024, collectively adding $47.8M in new exposure. UBS more than doubled its stake with a massive 2283.7% share increase, while Wells Fargo trimmed its position by nearly 60%, exiting $11.2M in value. The cluster shows strong net institutional accumulation despite one notable sell-off.
Key Financial Metrics
Institutional Positions
Net institutional flow: $36.6M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +71% | $58.6M | $18.6M |
| Schwab | DOUBLED | +134.4% | $1.3M | $640.0K |
| UBS | DOUBLED | +2283.7% | $30.1M | $28.6M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Wells Fargo | TRIM | -59.6% | $17.1M | -$11.2M |
Key Facts
- Morgan Stanley added $18.6M (71% share increase), growing its stake to 2.81M shares worth $58.6M
- UBS DOUBLED its position with a 2283.7% increase, adding $28.6M in value to reach $30.1M
- Schwab DOUBLED its stake with a 134.4% increase, adding $640K to reach $1.3M
- Wells Fargo trimmed 59.6% of its holdings, reducing position value from $17.1M to $5.9M (-$11.2M)
- Net institutional flow: +$36.6M (buyers added $47.8M, seller reduced by $11.2M)
Financial Impact
Three institutions added $47.8M in new positions while one reduced by $11.2M, resulting in net accumulation of $36.6M
Risk Factors
- The cluster is dominated by passive investors, which may reflect index rebalancing rather than fundamental conviction
- Wells Fargo’s significant trim could indicate profit-taking or risk-off behavior ahead of upcoming catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-GMAB-2024-Q4 |
Track record
31 reports on GMAB
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers